Ge-gen decoction alleviates primary dysmenorrhoea symptoms in a rat model.

Background: Existing treatments for primary dysmenorrhoea (PD), such as NSAIDs, impart side effects. Ge-Gen decoction (GGD), a traditional chinese medicine, has shown promise in treating PD, but its exact mechanisms remain unclear. Here, we aimed to investigate the efficiency of GGD in alleviating PD using a rat model to understand its precise mechanism of action. Methods: We established a rat model of dysmenorrhoea induced by oestradiol and oxytocin. The PD rats were administered GGD or Ibuprofen (positive control) intragastrically once daily for seven consecutive days. Serum levels of prostaglandin E2 (PGE2), prostaglandin F2 alpha (PGF2a), β-endorphin (β-EP), thromboxane B2 (TXB2), 6-keto-prostaglandin Fla (6-keto-PGF1a) were determined using an enzyme-linked immunosorbent assay (ELISA). The expression levels of oestrogen receptor alpha (ERa) and cyclooxygenase-2 (COX-2) in uterine tissue were measured using immunohistochemical assays, and those of phosphorylated and total extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) were assessed using western blot analysis. Results: Treatment with GGD significantly reduced writhing behaviour, histopathological scores, and levels of cOX-2, PGE2, and PGF2a in the serum of PD rats. Additionally, GGD increased β-EP content and inhibited ERK1/2 activation and ERa expression in uterine tissues. Conclusions: The results of this study suggest that GGD alleviates PD in rats by suppressing the COX-2-mediated release of PGE2 and PGF2a, modulating the ERa/ERK1/2/cOX-2 pathway, and increasing β-EP content. These results provide insights into the potential mechanisms of GGD in treating PD and support its further investigation as an alternative therapy for this condition. [ABSTRACT FROM AUTHOR]